share_log

AngioDynamics' (NASDAQ:ANGO) Earnings Are Weaker Than They Seem

AngioDynamics' (NASDAQ:ANGO) Earnings Are Weaker Than They Seem

AngioDynamics(納斯達克股票代碼:ANGO)的收益低於預期
Simply Wall St ·  2023/10/17 08:56

Despite announcing strong earnings, AngioDynamics, Inc.'s (NASDAQ:ANGO) stock was sluggish. We think that the market might be paying attention to some underlying factors are concerning.

儘管宣佈了強勁的收益,安吉奧動力公司的S納斯達克(Sequoia Capital:ANGO)股價低迷。我們認為,市場可能正在關注一些令人擔憂的潛在因素。

See our latest analysis for AngioDynamics

查看我們對AngioDynamics的最新分析

earnings-and-revenue-history
NasdaqGS:ANGO Earnings and Revenue History October 17th 2023
NasdaqGS:Ango收益和收入歷史2023年10月17日

The Impact Of Unusual Items On Profit

異常專案對利潤的影響

For anyone who wants to understand AngioDynamics' profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from US$18m worth of unusual items. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. Which is hardly surprising, given the name. We can see that AngioDynamics' positive unusual items were quite significant relative to its profit in the year to August 2023. All else being equal, this would likely have the effect of making the statutory profit a poor guide to underlying earnings power.

對於任何想要了解AngioDynamic利潤超出法定數位的人來說,重要的是要注意到,在過去12個月中,從價值1800萬美元的不尋常專案中獲得了法定利潤。雖然有更高的利潤總是好事,但不尋常的東西帶來的巨大貢獻有時會挫傷我們的熱情。當我們分析全球絕大多數上市公司時,我們發現重大的不尋常專案往往不會重複。考慮到這個名字,這並不令人驚訝。我們可以看到,在截至2023年8月的一年中,AngioDynamic的積極異常專案與其利潤相比相當重要。在其他條件不變的情況下,這可能會使法定利潤成為衡量潛在盈利能力的糟糕指標。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道,分析師對未來盈利能力的預測是什麼。幸運的是,您可以單擊此處查看基於他們估計的未來盈利能力的互動圖表。

Our Take On AngioDynamics' Profit Performance

我們對AngioDynamic利潤表現的看法

As we discussed above, we think the significant positive unusual item makes AngioDynamics' earnings a poor guide to its underlying profitability. For this reason, we think that AngioDynamics' statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. On the bright side, the company showed enough improvement to book a profit this year, after losing money last year. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you'd like to know more about AngioDynamics as a business, it's important to be aware of any risks it's facing. You'd be interested to know, that we found 1 warning sign for AngioDynamics and you'll want to know about this.

正如我們上面討論的,我們認為重要的積極的不尋常專案使AngioDynamic的收益不能很好地反映其潛在的盈利能力。出於這個原因,我們認為,AngioDynamic的法定利潤可能是其潛在盈利能力的不良指引,可能會給投資者帶來過於積極的公司印象。好的一面是,該公司在去年虧損後,表現出了足夠的改善,今年實現了盈利。歸根結底,如果你想正確地瞭解這家公司,除了以上幾個因素之外,考慮其他因素也是至關重要的。如果你想更多地瞭解AngioDynamic作為一家企業,瞭解它面臨的任何風險是很重要的。你會有興趣知道的,我們發現血管動力學的1個警告標誌你會想知道這一點的。

Today we've zoomed in on a single data point to better understand the nature of AngioDynamics' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了一個數據點,以更好地瞭解AngioDynamic的利潤性質。但如果你有能力將注意力集中在細枝末節上,總會有更多的東西需要發現。例如,許多人認為高股本回報率是有利的商業經濟指標,而另一些人則喜歡“跟著錢走”,尋找內部人士正在買入的股票。所以你可能想看看這個免費擁有高股本回報率的公司的集合,或內部人士正在購買的這份股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論